drugset / Trial / NCT06193434
A First In Human (FIH) Study of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients
Timeline
- Start
- 2024-01-05
- Primary completion
- 2025-08-20
- Completion
- 2025-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dupilumab | Monoclonal antibody | — | — |
| Subject | IBI356 | Unknown | — | — |